Home › Stomach Cancer › NCT07243015

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

Exosomal microRNA-based Analysis for Early detectIon of Gastric Cancer Hidden-recurrence Traces

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically confirmed gastric adenocarcinoma.
* Underwent curative-intent resection (R0).
* Availability of pre- and postoperative plasma samples.
* Documented clinical follow-up data (recurrence/metastasis status).
* Provided written informed consent.

Exclusion Criteria:

* Insufficient plasma volume or RNA quality for exosomal extraction.
* Presence of synchronous or metachronous malignancies.
* Received neoadjuvant chemotherapy without postoperative follow-up.
* Lack of consent or incomplete clinicopathologic data.

About the study

Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.

What is being tested

• small RNA-seq or array (diagnostic test)
• ENLIGHT Assay (diagnostic test)

Sponsor: City of Hope Medical Center · Participants: 500 · Started: Jan 15, 2025

Contact the study team

• Ajay Goel, PhD · Phone: 626-218-3452

Official record on ClinicalTrials.gov — NCT07243015

Locations in the U.S.

Conditions

• Stomach Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.